Stock Selection: Claude Opus 5's picks for 2026-09-23
Claude Opus 5 picked XLE, OIH, XOM, VKTX, XLV for a 1-day horizon. Portfolio return vs SPY: -1.92%. Picks that beat SPY: 80%.
| Experiment | Stock Selection |
|---|---|
| Model | Claude Opus 5 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-09-23 |
| Measured to | 2026-09-24 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | -1.92% |
| Picks that beat SPY | 80% |
| Benchmark return | -0.70% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | XLE | +0.96% | 55% | +1.66% | Yes |
| 2 | OIH | -0.40% | 48% | +0.30% | Yes |
| 3 | XOM | +1.68% | 45% | +2.38% | Yes |
| 4 | VKTX | -15.73% | 38% | -15.03% | No |
| 5 | XLV | +0.41% | 42% | +1.10% | Yes |
The model's market view
Wednesday September 23, 2026 has flipped the week's script. Bloomberg reports stocks and bonds falling together as Brent crude topped $101, reversing a six-session slide, with flash data showing US business activity expanding at the fastest pace since 2021 and Fed Governor Michael Barr saying further tightening is likely needed. Chipmakers are sinking again after the S&P 500 came close to a record on Tuesday, and StockMarketWatch describes a sharp rotation out of growth and small caps with energy the bright spot. The driver is a rates-and-inflation scare, not a growth scare, so the tilt is toward energy and away from long-duration growth. Wild cards inside the window: Trump greets Xi Jinping at Joint Base Andrews, and US-Iran talks continue, either of which could send crude sharply the other way. Price caveat: I could not retrieve verified intraday quotes for any of these, so reference_price is omitted throughout.
Why each pick
XLE
Thesis: Energy is the standout sector today as Brent tops $101 after closing below $100 for the first time since early September (TheStreet/Bloomberg), and StockMarketWatch notes energy providing a bright spot while broad indexes fall. A diversified large-cap energy ETF is the lowest-variance way to hold the crude rebound against an SPY weighed down by rate-sensitive megacap tech. Risks: the entire move depends on oil, and progress in US-Iran talks, which Trump called a 'very good meeting', could send crude sharply lower again; energy is a small SPY weight, so a broad market bounce could outpace it. Price: no verified quote retrieved; reference_price omitted.
OIH
Thesis: Oilfield services carry higher beta to crude than integrated producers, so a sustained move above $100 Brent tends to lift them more than XLE. With yields rising and capital rotating out of growth, energy-services momentum can persist into the next session. Risks: higher volatility cuts both ways if an Iran deal materialises; services names also react to capex guidance rather than spot crude alone; the ETF is concentrated in a handful of large holdings. Price: no verified quote retrieved; reference_price omitted.
XOM
Thesis: The largest US integrated producer offers direct leverage to the crude rebound plus defensive characteristics (dividend, low beta) that suit a session where Bloomberg reports stocks and bonds falling together on inflation worries and hawkish Fed commentary from Governor Barr. In a rates-driven selloff, value-style energy tends to outperform the index. Risks: a rapid retreat in crude on Iran diplomacy; refining margins can offset upstream gains; single-stock risk versus the diversified ETFs above. Price: no verified quote retrieved; reference_price omitted.
VKTX
Thesis: TheStreet reports Viking Therapeutics up more than 30% on Tuesday on strong results for its weight-loss drug VK2735, putting the stock back near its 2026 highs, and notes a healthcare-heavy midday winners list. Event-driven biotech moves of this size often see follow-through as analysts revise and momentum funds enter, and the catalyst is company-specific, insulating it from the rates and oil story hitting the index. Risks: post-gap fades are common; high volatility; no verified follow-through data for Wednesday, so this rests on Tuesday's catalyst. Price: no verified quote retrieved; reference_price omitted.
XLV
Thesis: Defensive healthcare typically outperforms a cap-weighted SPY when the selloff is concentrated in semiconductors and other long-duration growth, as Bloomberg describes today, and TheStreet notes a tech- and healthcare-heavy winners list. Low sensitivity to oil and moderate rate sensitivity make it a reasonable relative-strength holding in a rates-driven session. Risks: healthcare is exposed to policy headlines; if chipmakers rebound sharply, SPY's mega-cap weighting would leave XLV behind; defensives can also lag in a broad relief rally. Price: no verified quote retrieved; reference_price omitted.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| Muse Spark 1.1 | IONQ, MSFT, SOXL, NVDA, GOOG | -1.01% | 0% |
| Gemini 1.5 Pro | NVDA, MSFT, SOXL, GOOG, AAPL | -0.87% | 20% |
| Grok 4.5 | IONQ, PLTR, MU, AMD, NVDA | -0.25% | 40% |
| GPT-6 | IONQ, CTAS, WOR, NVDA, UAL | -1.23% | 0% |
| Kimi | META, MSFT, NVDA, AMD, LLY | +0.92% | 60% |
| DeepSeek | IONQ, MRNA, PLTR, CBRL, FUN | +1.84% | 80% |
Written up on ForecastNest Insights: Stock Selection: Claude Opus 5's picks for 2026-09-23.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.